CLINICAL TRIALS PROFILE FOR PORTIA-21

All Clinical Trials for Portia-21

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00117273 ↗	A Study to Evaluate Suppression of the Pituitary-Ovarian Axis With Three Different Oral Contraceptive Regimens	Completed	Duramed Research	Phase 3	2005-06-01	This is a randomized, open-label study to evaluate pituitary ovarian suppression in healthy, reproductive-aged women using three different regimens of oral contraceptives (OCs). Two extended regimen OCs, Seasonale (levonorgestrel/ethinyl estradiol 0.15/0.03 mg for 84 days followed by 7 days of placebo), and Seasonique (levonorgestrel/ethinyl estradiol 0.15/0.03 mg for 84 days followed by 7 days of ethinyl estradiol 0.01 mg), and a 28-day regimen OC, Portia (levonorgestrel/ethinyl estradiol 0.15/0.03 mg for 21 days followed by 7 days of placebo).
NCT00196365 ↗	A Study to Evaluate the Efficacy of Seasonique for the Treatment of Cyclic Pelvic Pain	Completed	Duramed Research	Phase 3	2005-01-01	This study is being conducted to evaluate the effects of treatment with Seasonique an extended-regimen oral contraceptive that utilizes low dose ethinyl estradiol during the typical hormone-free interval. Patients will receive 26 weeks of treatment. The overall study duration will be approximately 9 months. Patients will be required to record menstrual pain in a daily diary.
NCT01170390 ↗	Oral Contraceptives and Body Mass Index	Completed	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	Phase 4	2009-09-01	The main hypothesis for this study is that increased Body Mass Index (BMI) alters oral contraceptive metabolism in a manner which results in decreased effectiveness in obese women.
NCT01170390 ↗	Oral Contraceptives and Body Mass Index	Completed	Oregon Health and Science University	Phase 4	2009-09-01	The main hypothesis for this study is that increased Body Mass Index (BMI) alters oral contraceptive metabolism in a manner which results in decreased effectiveness in obese women.

Clinical Trial Conditions for Portia-21

Condition Name

Condition Name for Portia-21
Intervention	Trials
Healthy	1
Healthy Female Volunteers	1
Healthy Females	1
HIV Infections	1

Condition MeSH

Condition MeSH for Portia-21
Intervention	Trials
HIV Infections	1
Body Weight	1
Pelvic Pain	1
Dysmenorrhea	1

Clinical Trial Locations for Portia-21

Trials by Country

Trials by Country for Portia-21
Location	Trials
United States	21

Trials by US State

Trials by US State for Portia-21
Location	Trials
Oregon	2
Florida	2
Texas	2
Connecticut	1
New York	1

Clinical Trial Progress for Portia-21

Clinical Trial Phase

Clinical Trial Phase for Portia-21
Clinical Trial Phase	Trials
Phase 4	1
Phase 3	2
Phase 1	4

Clinical Trial Status

Clinical Trial Status for Portia-21
Clinical Trial Phase	Trials
Completed	7

Clinical Trial Sponsors for Portia-21

Sponsor Name

Sponsor Name for Portia-21
Sponsor	Trials
Pfizer	2
Duramed Research	2
Weill Medical College of Cornell University	1

Sponsor Type

Sponsor Type for Portia-21
Sponsor	Trials
Industry	5
Other	4
NIH	1

Portia-21 Market Analysis and Financial Projection

Last updated: April 27, 2026

PORTIA-21: Clinical Trial Update, Market Analysis, and Revenue Projection

What is PORTIA-21?

Insufficient information is available to identify PORTIA-21’s active ingredient, indication, mechanism, sponsor, trial registry IDs, endpoints, or authorization status. Without those fundamentals, clinical-trial status mapping, competitor landscape construction, and market sizing cannot be completed to a complete and accurate standard.

What is PORTIA-21’s clinical-trial status update?

No complete and accurate trial dataset (e.g., ClinicalTrials.gov/CTIS/EudraCT IDs, trial phases, enrollment status, topline dates, or investigator sites) is available to produce a usable clinical update.

How does PORTIA-21 compete in its addressable market?

No indication and no chemical entity information is available, so the relevant competitor class, standard-of-care mix, pricing basis, and access dynamics cannot be specified.

What is the market forecast for PORTIA-21?

A market projection requires at least: indication, target patient numbers, launch year, dosing regimen, peak share assumptions, WAC and net price structure, payer coverage, and expected label duration. None of these are available for PORTIA-21.

What revenue scenarios can be modeled?

Revenue modeling requires the same inputs plus timeline (phase completion, NDA/BLA submission, approval date), probability-of-success per phase, and market uptake curve. No such inputs exist for PORTIA-21 in the available data.

Key Takeaways

• PORTIA-21 cannot be analyzed for clinical-trial status, competitive positioning, or market projection without identification of its active ingredient and indication.
• No sponsor, trial registry entries, endpoints, or regulatory milestones are available to support an evidence-based update.
• No pricing, dosing, patient population, or market-access assumptions exist to build a defensible forecast.

FAQs

1. Is PORTIA-21 approved in any jurisdiction?
2. Which clinical trials for PORTIA-21 are active and at what phases?
3. What indication and mechanism does PORTIA-21 target?
4. Who are PORTIA-21’s closest competitors by mechanism and line of therapy?
5. What is the expected launch timeline and peak sales range?

References

[1] No cited sources available.